In a landmark randomized controlled trial, Vrieze et al. reported that individuals with metabolic syndrome who received allogeneic FMT from lean donors exhibited a significant improvement in peripheral insulin sensitivity six weeks after treatment, accompanied by an enrichment in butyrate-producing bacteria, such as Roseburia intestinalis [67]. Here, INS is linked to metabolic syndrome.